Physician profile
Matthew Hueman
NPI 1780621656
$1,005.22
in general payments reported to CMS, 2019-2025
12 companies · $43.52 in 2025
The $43.52 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $962 · 2025: $43.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molli Surgical (US) INC | $266.59 | 2024 | |
| Myriad Genetic Laboratories, INC. | $246.10 | 2024 | Myrisk |
| Endomagnetics LTD | $153.45 | 2024 | Magtrace, Magseed |
| Novartis Pharmaceuticals Corporation | $107.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.50 | 2024 | Enhertu, Onglyza |
| Merck Sharp & Dohme LLC | $44.18 | 2024 | Keytruda |
| Incyte Corporation | $27.16 | 2024 | Monjuvi, Jakafi |
| Glaxosmithkline, LLC. | $26.46 | 2024 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $23.71 | 2024 | Enhertu |
| Genentech USA, INC. | $22.77 | 2025 | Tecentriq |
| Servier Pharmaceuticals LLC | $20.57 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.67 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hueman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.